2017 Conference on Retroviruses and Opportunistic Infections*

February 13-16, 2017; Seattle, Washington
Get up to date on the latest HIV data with rapid Capsule Summaries, downloadable slidesets, and live, expert-led Webinars covering key studies from Seattle.

New Data from CROI 2017

Capsules

The combination drove a strong immune response and detectable viremia with no additional toxicity compared with vaccines alone.

Released: February 19, 2017

Follow-up observational study detects small yet significant CVD risk with 5-year cumulative use of darunavir/ritonavir but no risk with atazanavir/ritonavir.

Released: February 19, 2017

Although acute HCV incidence declined by 51%, syphilis diagnoses increased by 41% in Dutch public health STD clinics between 2015 and 2016.

Released: February 22, 2017

No evidence of increased HCC incidence linked to DAA use in this observational Spanish cohort; results may reflect uptick in use of HCV therapy in advanced liver disease.

Released: February 17, 2017

Efficacy and safety of bictegravir plus TAF/FTC comparable to that of DTG plus TAF/FTC.

Released: February 23, 2017

After receiving TMC278 LA injections, 68% of participants strongly agreed they would use an injectable prophylaxis in the future.

Released: February 23, 2017

Ad hoc analysis suggests continued use of cabotegravir plus rilpivirine. following induction-maintenance treatment safe and effective.

Released: February 19, 2017

Open-label extension phase of women-only WAVES study observed improvement in bone and renal markers with switch to EVG/COBI/FTC/TAF.

Released: February 19, 2017

Novel monoclonal antibody appears less effective in patients with low baseline CD4+ cell counts.

Released: February 19, 2017

Two-drug regimen maintained virologic suppression in 95% of patients over 48 weeks and improved bone turnover markers despite increase in low-grade, drug-related adverse events following switch.

Released: February 17, 2017

Extended follow-up reverses noninferiority previously observed at Week 24.

Released: February 17, 2017

Efficacy of elsulfavirine plus TDF/FTC comparable to that of EFV plus TDF/FTC but with lower frequency of drug-related AEs and specific CNS events.

Released: February 19, 2017

EVG/COBI/FTC/TAF continued to be associated with improvements in renal and bone markers vs EVG/COBI/FTC/TDF through 144 weeks.

Released: February 23, 2017

97% of patients maintained virologic suppression following switch from initial triple-therapy ART to dolutegravir plus lamivudine with a low incidence of serious adverse events.

Released: February 22, 2017

Doravirine was well tolerated with very low incidence of resistance.

Released: February 17, 2017

Patient with an acute OI experienced virologic failure on dolutegravir-based therapy followed by subsequent resuppression with ART intensification.

Released: February 17, 2017

High bone turnover and urinary phosphate wasting could identify patients most likely to benefit from TDF to TAF switch.

Released: February 21, 2017
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by independent educational grants from
Gilead Sciences
Merck & Co., Inc.
Theratechnologies Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?